Presentation reveals advancements in methylation profiling for CNS tumors, suggesting improved classification and diagnosis.
Advances in genomic DNA methylation profiling have revolutionized brain tumor classification, enhancing diagnostic accuracy and personalized medicine. This presentation will provide case-based examples of how methylation arrays have become an essential part of the workup for CNS tumors. It will also present two new approaches to methylation profiling, nanopore and TET-assisted pyridine borane sequencing (TAPS), and how these new technologies are poised to replace much of our current molecular armamentarium. Citation Format: Craig Horbinski. The present and future of methylation profiling in CNS tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Brain Cancer; 2026 Mar 23-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(6_Suppl):Abstract nr IA007.
No takes yet. Share an insight, caveat, or question.
Craig M. Horbinski (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: